Pharmaceutical Intermediate Favipiravir Purity Favipiravir Raw Powder Favipiravir

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Favipiravir
• Product Name: Favipiravir
• Name: Favipiravir Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Treatment Pneumonia;Pharmaceutical
• Specific: COA
• Test Method: HPLC 99%
• Shelf Life: 2 Years
• CAS No.: 259793-96-9
• Mf: C5h4fn3o2
• MW: 157.1025632
• Melting Point: 187ºC to 193ºC
• Density: 1.78
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical Intermediate Favipiravir Purity Favipiravir Raw Powder Favipiravir

Product Description

Product Details

Product name	Favipiravir
Cas number	259793-96-9
Apperance	White powder
MF	C5H4FN3O2
MW	157.1025632

Favipiravir, also known as T705, or Avigan, is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus,   foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses   has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them.

Application&Function

Function of Fabirovir
Activity against enteroviruses and Rift Valley fever virus has also been demonstrated. The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. 
Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.S.
Application of Fabirovir
Fabirovir is an influenza treatment, but it has a different mechanism of action from many anti-influenza drugs.
Drugs such as tamiflu prevent infection by stopping the proliferating virus from burbling into cells, while familavir stops the virus itself from multiplying by blocking gene replication in cells.

Specification